Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial

Completed

Conditions studied: Ventricular Tachycardia, Cardiovascular Diseases, Arrythmia, CVD

In brief

The ABCD clinical study (ClinicalTrials.gov Identifier NCT00187291) was designed to determine if a T-Wave Alternans (TWA) test is equivalent to an Electrophysiology Study (EPS) in predicting life-threatening heart rhythms in patients with ischemic heart disease, left ventricular dysfunction, and non-sustained tachycardia. The purpose of the ABCD Genetic sub-study is to identify genetic markers that predict TWA status and arrhythmia risk in this same population.

Key facts

Study ID

NCT00583297

Run by

CardioDx

People needed

400

Starts

2007-01-01

Expected to finish

2009-12-01

Last updated by the study team

2018-02-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects previously enrolled in the ABCD trial sponsored by St. Jude Medical (ClinicalTrials.gov Identifier NCT00187291)
• patients with ischemic heart disease
• left ventricular ejection fraction (LVEF) < 40%
• non-sustained ventricular tachycardia

You may not qualify if…

• Individuals who were not previously enrolled in the ABCD trial are not eligible for this genetic sub-study.

Where it is running

• MetroHealth Medical Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.